open access

Vol 90, No 2 (2019)
ORIGINAL PAPERS Obstetrics
Published online: 2019-02-28
Get Citation

Expression of Cripto-1 in the placenta and its role in placenta accreta and placenta previa

Lingling Jiang, Xiaoya Wu, Jianying Yan, Rongxin Chen, Qing Han, Qinjian Zhang
DOI: 10.5603/GP.2019.0015
·
Pubmed: 30860275
·
Ginekol Pol 2019;90(2):86-92.

open access

Vol 90, No 2 (2019)
ORIGINAL PAPERS Obstetrics
Published online: 2019-02-28

Abstract

Objectives: This study Aims to explore the role of placental Cripto-1 in the incidence of an adherent placenta. 

Material and methods: Ten pregnant women with placenta increta, 20 pregnant women with placenta previa and 30 women with normal pregnant were enrolled in this study. Reverse transcription-polymerase chain reaction (RT-PCR) was used to measure the expression of Cripto-1 in the placenta while as the analysis of placental Cripto-1 was performed by Western blotting 

Results: The placenta increta group showed higher levels of Cripto-1 in the center of the increta as compared to the non-implantation area. The level of placental Cripto-1 in the placenta increta was higher than that of the placenta accrete. The expression of placental Cripto-1 in the placenta increta and placenta previa groups was higher than that of control. 

Conclusions: Placental Cripto-1 is involved in the regulation of placental tissue invasion. Additionally, excessive placental growth or penetration into the myometrium are likely to be involved in the development of placenta increta. 

Abstract

Objectives: This study Aims to explore the role of placental Cripto-1 in the incidence of an adherent placenta. 

Material and methods: Ten pregnant women with placenta increta, 20 pregnant women with placenta previa and 30 women with normal pregnant were enrolled in this study. Reverse transcription-polymerase chain reaction (RT-PCR) was used to measure the expression of Cripto-1 in the placenta while as the analysis of placental Cripto-1 was performed by Western blotting 

Results: The placenta increta group showed higher levels of Cripto-1 in the center of the increta as compared to the non-implantation area. The level of placental Cripto-1 in the placenta increta was higher than that of the placenta accrete. The expression of placental Cripto-1 in the placenta increta and placenta previa groups was higher than that of control. 

Conclusions: Placental Cripto-1 is involved in the regulation of placental tissue invasion. Additionally, excessive placental growth or penetration into the myometrium are likely to be involved in the development of placenta increta. 

Get Citation

Keywords

Cripto-1; placenta increta; placenta previa; pathogenesis; pregnancy

About this article
Title

Expression of Cripto-1 in the placenta and its role in placenta accreta and placenta previa

Journal

Ginekologia Polska

Issue

Vol 90, No 2 (2019)

Pages

86-92

Published online

2019-02-28

DOI

10.5603/GP.2019.0015

Pubmed

30860275

Bibliographic record

Ginekol Pol 2019;90(2):86-92.

Keywords

Cripto-1
placenta increta
placenta previa
pathogenesis
pregnancy

Authors

Lingling Jiang
Xiaoya Wu
Jianying Yan
Rongxin Chen
Qing Han
Qinjian Zhang

References (15)
  1. Lim BH, Palacios-Jaraquemada JM. The morbidly adherent placenta--a continuing diagnostic and management challenge. BJOG. 2015; 122(12): 1673.
  2. Garmi G, Salim R. Epidemiology, etiology, diagnosis, and management of placenta accreta. Obstet Gynecol Int. 2012; 2012: 873929.
  3. Leveno KJ, Cunningham FG, Norman FG, et al. Williams Manual of Obstetrics, 24 st edition. McGraw-Hill Education - Europe .
  4. Dunjin C, Chunhong S. Placenta Accreta.Chunhong S. ed. Hunan Science and Technology Press, Changsha : 1–6.
  5. Sakinci M, Kuru O, Tosun M, et al. Clinical analysis of emergency peripartum hysterectomies in a tertiary center. Clin Exp Obstet Gynecol. 2014; 41(6): 654–658.
  6. Parra-Herran C, Djordjevic B. Histopathology of Placenta Creta: Chorionic Villi Intrusion into Myometrial Vascular Spaces and Extravillous Trophoblast Proliferation are Frequent and Specific Findings With Implications for Diagnosis and Pathogenesis. Int J Gynecol Pathol. 2016; 35(6): 497–508.
  7. Ciccodicola A, Dono R, Obici S, et al. Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells. EMBO J. 1989; 8(7): 1987–1991.
  8. Bandeira CL, Urban Borbely A, Pulcineli Vieira Francisco R, et al. Tumorigenic factor CRIPTO-1 is immunolocalized in extravillous cytotrophoblast in placenta creta. Biomed Res Int. 2014; 2014: 892856.
  9. Kim KR, Jun SY, Kim JY, et al. Implantation site intermediate trophoblasts in placenta cretas. Mod Pathol. 2004; 17(12): 1483–1490.
  10. Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 2009; 5(8): 1145–1168.
  11. Qinjian Z, Jianying Y. Role of E-cadherin in Placenta Accreta [J]. Chinese Journal of Perinatal Medicine. 2015; 4: 306–309.
  12. Bianco C, Strizzi L, Ebert A, et al. Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst. 2005; 97(2): 132–141.
  13. Gray PC, Vale W. Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis. FEBS Lett. 2012; 586(14): 1836–1845.
  14. Wallace AE, Fraser R, Cartwright JE. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Hum Reprod Update. 2012; 18(4): 458–471.
  15. Lee CC, Jan HJ, Lai JH, et al. Nodal promotes growth and invasion in human gliomas. Oncogene. 2010; 29(21): 3110–3123.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl